Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

133.23 +1.69 (+1.28%)
Streaming Delayed Price Updated: 2:41 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,964,679
Open 132.00
Bid (Size) 133.23 (1)
Ask (Size) 133.24 (2)
Prev. Close 131.54
Today's Range 131.85 - 133.26
52wk Range 77.95 - 148.15
Shares Outstanding N/A
Dividend Yield 1.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
7 Sorry Biotech Stocks Set to Make Investors Sad
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace

Performance

YTD
+30.48%
+30.48%
1 Month
-6.15%
-6.15%
3 Month
+6.36%
+6.36%
6 Month
+26.30%
+26.30%
1 Year
+64.41%
+64.41%

More News

Read More
Here's My Top Growth Stock to Buy Right Now
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Via Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Via Benzinga
7 A-Rated Stock Picks With Huge Upside Potential
Via InvestorPlace
Is Viking Therapeutics a Millionaire-Maker?
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
Via InvestorPlace
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
Via Benzinga
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Via The Motley Fool
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
Via Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Via Benzinga
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
Via Investor's Business Daily
3 Hot Growth Stocks That Will Make You Forget About AMD
Via InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
Via Benzinga
3 Dow Jones Stocks to Buy at 52-Week Lows in July
Via InvestorPlace
Topics Stocks
Exposures US Equities
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.